Our Business

With the rapidly growing global metabolic disease epidemic, which includes diabetes and obesity, there is a significant need to bring safer, more effective medications to physicians and patients world-wide. InteKrin’s business strategy, under the guidance of InteKrin’s experienced Management Team and world-class Scientific Advisory Board (SAB) and Board of Directors (BOD), is to build a robust portfolio of high-potential products through in-licensing clinical-stage therapeutic candidates to meet the growing patient needs. The InteKrin team uses its capabilities to rapidly and effectively shepherd these therapeutic candidates through critical development stages to de-risk them and maximize their commercial potential.   Read More

Recent News